Exploring Editas' strategic directions at JPM2024, we delve into the future of gene editing and CRISPR's potential to cure blindness. Is it science fiction or a medical breakthrough? We analyze EDIT stock's recent crash and assess new gene editing stocks, exploring whether they're worth investing in.